Keyword: Keytruda

Keytruda's U.S. NSCLC sales might start to fall as soon as early 2020, one analyst says, as I-O rivals eat into its share based on recent successes.

Pfizer and Merck KGaA's immuno-oncology agent Bavencio failed another gastric cancer study, this time as a maintenance treatment after chemotherapy.

Wall Street analysts pressed Merck for details about whether Keytruda can maintain strong growth as it faces rivals in lung and breast cancer.

Merck is chopping 500 jobs nationwide as part of a continued shift to focus more on innovative drugs. The cuts are effective Jan. 3.

Humira has been topping pharma's sales charts, but in a few years it'll be passed by Keytruda and several other meds, a GlobalData forecast shows.

Sanofi slims down in Japan. We examine Big Pharma CEOs' Chinese names. Positive data came out from Astellas, Eisai and Chi-Med at ESMO.

Riding high on FDA and EU approvals in triple-negative breast cancer, Roche’s Tecentriq hoped for a win from NICE. The drugmaker didn’t get it.

If this year’s ASCO meeting was “quiet,” as some contended, this year’s ESMO was anything but.

Merck and Eisai are out with the expanded data that recently snagged their Keytruda-Lenvima combo three endometrial cancer go-aheads.

Merck’s Keytruda may have come up short in metastatic TNBC over the weekend, but in the pre-surgery setting, it posted a first-of its-kind win.